13 Apr 2023
#Lifescience

ANTARES VISION GROUP, THROUGH RFXCEL, BEGINS PARTNERSHIP WITH RENOWN HEALTH NETWORK FOR DSCSA-COMPLIANT PHARMACEUTICAL TRACKING

ANTARES VISION GROUP, THROUGH RFXCEL, BEGINS PARTNERSHIP WITH RENOWN HEALTH NETWORK FOR DSCSA-COMPLIANT PHARMACEUTICAL TRACKING

rfxcel, part of Antares Vision Group, will implement DSCSA compliance solutions to help ensure pharmacies across the northern Nevada healthcare network comply with the regulations

Antares Vision Group announced that rfxcel has begun a partnership with Renown Health Foundation to implement compliance software so the network can track and trace pharmaceuticals in compliance with the Drug Supply Chain Security Act (DSCSA).

With rfxcel’s DSCSA compliance solutions, Renown Health’s medical groups and pharmacies will achieve real-time electronic tracing of drug products at the package level to identify and trace prescription drugs as they are distributed throughout the health system. This will enhance Renown’s ability to help protect patients from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.

Reno has been our home since 2018, and many of our employees live and work in the northern Nevada region,” said rfxcel CEO Glenn Abood.Renown is one of the leading not-for-profit healthcare organizations here and is the perfect partner to team with to give back to our community. We are excited about the opportunity to work with them and to help improve the health and well-being of our friends and neighbors.

Ensuring our patient’s medications are safe and legitimate is of the upmost importance to us,” said Renown’s Vice President of Pharmacy Services Adam Porath.When members of our community get involved in our work, it brings us all closer together. We are thankful that Antares Vision Group and rfxcel are partnering with us on our healing mission. They are making it possible for us to keep our patients safe, comply with the demanding DSCSA requirements, and respond quickly to changing supply chain requirements.